OVCHECK have secured a marker that can diagnose ovarian cancer with an accuracy of 95% or higher (sensitivity of 100% and specificity of 91%), and the project is currently in the clinical validation stage.

OVCHECK DEVELOPMENT PROCESS
Bertis is currently developing a highly accurate early ovarian cancer diagnosis technology with Seoul National University Hospital Gangnam Center.

The tumor markers CA125 and HE4, the conventional biomarker for ovarian cancer testing, have limitations in the early screening of ovarian cancer due to their low sensitivity and specificity.

Bertis is developing a technology that enables a more accurate diagnosis of ovarian cancer and is currently in the clinical verification stage by securing markers to diagnose ovarian cancer with more than 95% accuracy (100% sensitivity and 91% specificity).